GT Biopharma, Inc. reported on May 21, 2025, that it amended its Securities Purchase Agreement to increase its private offering of Series L Convertible Preferred Stock to 6,612 shares for a purchase price of $5,950,000, raising the total offering value to $6,611,111. The agreement also allows for additional purchases under Greenshoe Rights, totaling up to $24 million.